NCT04408040终止2 期
Use of Convalescent Plasma Collected From Donors Recovered From COVID-19 Virus Disease for Transfusion, as an Empirical and Preemptive Treatment During Viral Pandemic Outbreak
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Arms 1 & 2: Number of COVID-19 Infected Patients in Severe, High Risk & Health Care Provider Cohorts Who Survive the Infection
研究概览
简要总结
The plan is to transfuse COVID-19 infected patients with convalescent plasma and observe whether this will result in a significant improvement in clinical outcome in comparison to historical experience.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •* Documented COVID-19 infection by nasal pharyngeal sampling
- •* COVID-19 disease falling into one of the following groups:
- •* Critical disease: respiratory failure requiring mechanical ventilation, pressor support, or multiple organ dysfunction/failure
- •* Severe disease: tachypnea \>/=30 per min, O2 sats \/=40, age \>/=65 years
- •* Health Care Providers: health care providers at risk to exposure to COVID-19 infection or those with mild to non-severe disease
排除标准
- •History of IgA deficiency
- •History of anaphylatic reaction to blood product transfusion including hypersensitivity to immunoglobulin therapy
研究组 & 干预措施
Critical Patients
Other
干预措施: Convalescent Plasma (Biological)
Severe Patients
Other
干预措施: Convalescent Plasma (Biological)
High Risk
Other
干预措施: Convalescent Plasma (Biological)
Health Care Providers
Other
干预措施: Convalescent Plasma (Biological)
结局指标
主要结局
Arms 1 & 2: Number of COVID-19 Infected Patients in Severe, High Risk & Health Care Provider Cohorts Who Survive the Infection
时间窗: 30 days after initial treatment
Number of patients who survived the covid infection after treatment on study.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)Covid19NCT04554992The Methodist Hospital Research Institute350
已完成
2 期
Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19COVID-19NCT04438057Metro Infectious Disease Consultants103
已完成
2 期
Convalescent Plasma in the Treatment of COVID 19COVIDSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)CoronavirusNCT04343261Trinity Health Of New England48
Unknown
不适用
A Study to Evaluate the Safety and Efficacy of COVID-19 Convalescent Plasma (CCP) Transfusion to Prevent COVID-19 in Adult Recipients Following Hematopoietic Stem Cell TransplantationCOVID-19Hematopoietic Stem Cell TransplantationNCT05904067Institute of Hematology & Blood Diseases Hospital, China72
已完成
1 期
CoVID-19 Plasma in Treatment of COVID-19 PatientsCOVID 19NCT04355897The Christ Hospital22